J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes
Johnson & Johnson cites the 2005 switch to the ASP-plus 6% reimbursement model among its reasons for optimism despite Procrit’s recent performance. Aranesp is gaining on J&J brand; Procrit market share slipped to 61% in second quarter.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’